FBR Capital Remains Bullish on BioCryst Pharma (BCRX) Following Phase l Completion of BCX7353
Tweet Send to a Friend
FBR Capital reiterated an Outperform rating and $18.00 price target on BioCryst Pharma (NASDAQ: BCRX) following the company's announced completion ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
